Spots Global Cancer Trial Database for Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS

Official Title: A Prospective, Single Center, Open Label, Dose Escalation Phase I/IIa Study to Assess the Safety and Efficacy of an Intrathecal Administration of SCM-010 in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)

Study ID: NCT03696485

Conditions

Secondary Progressive Multiple Sclerosis (SPMS)

Interventions

SCM-010

Study Description

Brief Summary: Prospective, single center, open label, phase I/IIa escalating dose study. To evaluate the safety and efficacy of escalating doses of SCM-010 in subjects with SPMS.

Detailed Description: Twelve (12) SPMS subjects will be enrolled in this study in two dose cohorts. Each subject will receive SCM- 010 by intrathecal (IT) administration at baseline and will be followed up for 24 weeks for efficacy and 48 weeks for safety.